SGHT

Sight Sciences

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

3

Business Summary

Sight Sciences is a medical device company focused on developing and commercializing minimally invasive surgical and interventional technologies for ophthalmology. Its products are primarily used in the treatment of glaucoma and dry eye disease.

 


Analyze SGHT on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$272

Forward P/E

-

PEG

-

PRICE TO SALES

3.5

PRICE TO BOOK

4.2

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.90

Next Year EPS Growth Estimate

-$0.64

Next Year Revenue Growth Estimate

11.70%

Return on Equity (ROE)

-71.70%

FREE CASH FLOW

Operating Margin

-59.60%

Debt-to-Equity

0.6

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze SGHT on TradingView

Gainseekers Quantitative Analysis

Summary

Sight Sciences is a small-cap Healthcare company with a $272M market cap trading on the Nasdaq, currently unprofitable with an EPS of -$0.90 and a negative operating margin of -59.60%. The company has no P/E ratio and trades at 3.5x sales and 4.2x book value, while return on equity stands at -71.70%. With earnings expected in 3 days and projected sales growth of 11.70% next year, analysts maintain a positive stance with a 1.89 consensus rating and a $9.35 mean target price.

AI Exposure / Tech Reliance

As a Medical Devices company, its technology reliance is centered on medical device innovation rather than artificial intelligence exposure. AI does not appear to be a primary driver based on the provided metrics.

The Bull Case

The bull case rests on expected sales growth of 11.70% next year and improving EPS from -$0.90 to an estimated -$0.64, suggesting narrowing losses. Analyst sentiment is favorable with a 1.89 consensus rating and a target price of $9.35, while debt remains moderate with a 0.6 debt-to-equity ratio.

The Bear Case

The bear case centers on significant unprofitability, highlighted by a -59.60% operating margin and -71.70% return on equity. With negative earnings, no dividend support, and shares trading at 3.5x sales, the company faces execution risk ahead of its upcoming earnings report in 3 days.

Market Sentiment & Smart Money

Short Interest %

2.80%

Analyst Consensus

1.89

Average Analyst Price Target

$9.35

Institutional Ownership %

54.10%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.